Cartesian Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update

Core Insights - Cartesian Therapeutics is advancing its lead product, Descartes-08, through multiple clinical trials targeting autoimmune diseases, with a focus on myasthenia gravis (MG) and myositis [2][3][9] - The company reported a net loss of $130.3 million for the year ended December 31, 2025, compared to a net loss of $77.4 million in 2024, indicating increased operational expenses primarily due to ongoing clinical trials [6][13] Clinical Development Updates - The Phase 3 AURORA trial for Descartes-08 in MG is actively enrolling approximately 100 patients, aiming to demonstrate significant improvements in patient outcomes [2][3] - The Phase 2 TRITON trial for myositis is expected to initiate in the first half of 2026, with the FDA accepting the investigational new drug application [3][4] - The Phase 1/2 HELIOS pediatric trial for juvenile dermatomyositis is currently ongoing, with Descartes-08 having received Rare Pediatric Disease Designation from the FDA [4][9] Financial Performance - As of December 31, 2025, the company had approximately $126.9 million in cash and equivalents, expected to support operations into mid-2027 [6][8] - Research and development expenses increased to $58.0 million in 2025 from $45.1 million in 2024, reflecting the costs associated with the ongoing Phase 3 trial [6][13] - Total revenues for 2025 were reported at $2.8 million, a significant decrease from $38.9 million in 2024, primarily due to reduced collaboration and grant revenues [13] Corporate Governance - Adrian Bot was appointed to the Board of Directors, bringing extensive experience in biopharma, which aligns with the company's strategic goals [8] - Carsten Brunn was named Chairman of the Board, following the departure of the previous chair, indicating a shift in leadership to support the company's growth [8]